Lappaconitine, preparation method thereof, pharmaceutical composition and application of lappaconitine in antidepressant drugs

By extracting and isolating high-purity aconitine from the traditional Chinese medicine Aconitum carmichaelii and combining it with a drug composition, the problem of large side effects of existing antidepressants has been solved, achieving highly efficient and pure antidepressant activity, which is suitable for the development of antidepressant drugs.

CN118978484AActive Publication Date: 2024-11-19CHINA JAPAN FRIENDSHIP HOSPITAL
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411066530.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-19
Estimated Expiration
2044-08-05

AI Technical Summary

Technical Problem

Existing antidepressants have significant side effects and certain limitations in clinical application. The antidepressant activity of eugenol has not been fully studied and applied.

Method used

High-purity aconitine was extracted and isolated from Aconitum carmichaelii, a traditional Chinese medicine, and prepared by multi-step solvent extraction, chromatographic separation and reversed-phase high-performance liquid chromatography (RP-HPLC). The aconitine was then combined with a pharmacodynamically acceptable carrier or excipient to form a drug composition.

Benefits of technology

High-purine showed significant antidepressant activity in a mouse behavioral despair model experiment, which was superior to the positive control drug fluoxetine. It provides a simple, reproducible, and highly pure preparation method that is suitable for the development of antidepressant drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004979501880000021
    Figure BDA0004979501880000021
  • Figure BDA0004979501880000091
    Figure BDA0004979501880000091
  • Figure BDA0004979501880000111
    Figure BDA0004979501880000111
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, and discloses lappaconitine, a preparation method thereof, a pharmaceutical composition and application of the lappaconitine in antidepressant drugs. The C18 type diterpenoid alkaloid lappaconitine provided by the invention shows remarkable anti-depression activity in a mouse behavioral despair model experiment, is remarkably superior to a positive drug fluoxetine, and can be used for developing anti-depression drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and more specifically, relates to a C 18 A type diterpene alkaloid compound lappaconitine, a preparation method thereof, a pharmaceutical composition and application thereof in antidepressant drugs. Background Art

[0002] Nowadays, social competition is becoming increasingly fierce. High-intensity and high-pressure life has a serious impact on people's physical and mental health. Depression is gradually increasing and seriously affects people's normal work and life. At present, drugs for treating depression generally have large side effects and have certain limitations in clinical application.

[0003] As the first non-addictive analgesic drug developed in China, lappaconitine has the advantages of good analgesic activity, long-lasting effect, and few adverse reactions. It is widely used in the treatment of mild to moderate pain such as postoperative pain and cancer pain. At present, there are also relevant studies on the pharmacological activities of lappaconitine such as anti-arrhythmic, anti-inflammatory and anti-tumor, but there are no reports on its antidepressant activity.

[0004] The inventors prepared lappaconitine from the traditional Chinese medicine aconite, and found that it showed significant antidepressant activity in a mouse behavioral despair model experiment, which was better than the positive drug fluoxetine, and can be used to develop antidepressant drugs. Summary of the invention

[0005] In view of the shortcomings of the prior art, the present invention provides a C 18 The invention discloses a preparation method of a type diterpene alkaloid lappaconitine, a pharmaceutical composition and an application thereof in antidepressant drugs.

[0006] To achieve the above object, the technical solution of the present invention is as follows:

[0007] A lappaconitine having a structure shown in formula (1):

[0008]

[0009] It should be noted that the lappaconitine may be a compound, stereoisomer, tautomer or pharmaceutically acceptable salt including the structure shown in formula (1). That is, the compound including the structure shown in formula (1), and its stereoisomer, tautomer and pharmaceutically acceptable salt are all within the protection scope of the present application.

[0010] On the other hand, the present invention also provides a method for preparing the above-mentioned lappaconitine, wherein the lappaconitine is extracted and separated from aconite root.

[0011] In the above technical scheme, the preparation method of lappaconitine comprises the following steps:

[0012] S1. Take dried aconite root, add solvent to reflux and extract, combine the extracts and concentrate to obtain an extract;

[0013] S2, adding the extract to dilute hydrochloric acid to fully dissolve and suspend, filtering and removing impurities to obtain an acid aqueous solution; extracting the acid aqueous solution once with dichloromethane, filtering out the primary extract, and obtaining a filtered acid aqueous solution; adjusting the pH of the filtered acid aqueous solution to alkaline; and then performing a secondary extraction with dichloromethane to obtain a secondary extract;

[0014] S3, gradient eluting the secondary extract with a dichloromethane-methanol solution to obtain a fraction B; when detected by silica gel thin layer, the Rf value of the fraction B is 0.76-0.80;

[0015] S4, gradient eluting fraction B using a methanol-water mixed solution to obtain fraction B2;

[0016] When using silica gel thin layer analysis, the Rf value corresponding to fraction B2 was 0.45-0.49;

[0017] S5, gradient eluting fraction B2 with methanol-water solution to obtain fraction K3;

[0018] When using silica gel thin layer analysis, the K3 value corresponding to fraction B2 was 0.64-0.76;

[0019] S6. Separate the lappaconitine from fraction K3 using RP-HPLC (i.e., reversed-phase high performance liquid chromatography separation method); the mobile phase used in the RP-HPLC method is an acetonitrile-water mixed solution.

[0020] Furthermore, in step S2, the filtered acid aqueous solution is adjusted to a pH of 8-11 with sodium hydroxide; preferably, pH=9.

[0021] Furthermore, in step S2, the extract is added into 8-15 times the mass of dilute hydrochloric acid to be fully dissolved and suspended, and then filtered to remove impurities to obtain an acid aqueous solution.

[0022] Furthermore, the concentration of the dilute hydrochloric acid is 0.1-1.0%, preferably 0.5%.

[0023] Further, in step S3, the secondary extract is separated by silica gel column chromatography to obtain fraction B; based on the total volume of 100, the volume ratio of dichloromethane to methanol in the dichloromethane-methanol solution when fraction B is eluted (i.e. corresponding to fraction B) is (97:3)-(93:7); preferably, the volume ratio of dichloromethane to methanol is 95:5.

[0024] Furthermore, in step S4, the fraction B is separated by ODS column chromatography to obtain fraction B2; based on the total volume of 100, the volume ratio of methanol to water in the methanol-water mixed solution when fraction B2 is eluted (i.e., corresponding to fraction B2) is (25:75)-(35:65); preferably, the volume ratio of methanol to water is 30:70.

[0025] Furthermore, in step S4, the methanol-water mixed solution contains 0.01-1.1V% formic acid.

[0026] Preferably, in step S4, the methanol-water mixed solution contains 0.05V% formic acid.

[0027] Furthermore, in step S5, the fraction B2 is separated by gel column chromatography to obtain fraction K3; based on the total volume of 100, the volume ratio of methanol to water in the methanol-water solution when fraction K3 is eluted (i.e., corresponding to fraction K3) is (65:35)-(75:25); preferably, the volume ratio of methanol to water is 70:30.

[0028] Preferably, the gel column chromatography is Sephadex LH-20 gel column chromatography.

[0029] Furthermore, in step S6, the volume ratio of acetonitrile to water in the acetonitrile-water mixed solution is (44:56)-(48:52); and the acetonitrile-water mixed solution contains 0.01-0.5V% trifluoroacetic acid.

[0030] Preferably, in step S6, the volume ratio of acetonitrile to water in the acetonitrile-water mixed solution is 46:54.

[0031] Preferably, in step S6, the acetonitrile-water mixed solution contains 0.1V% trifluoroacetic acid.

[0032] Furthermore, in step S1, the solvent is 88-98V% ethanol aqueous solution, the mass of the added solvent is 8-10 times that of the aconite root, the number of reflux extractions is 2-4 times, and each extraction takes 1-3 hours.

[0033] In another aspect, the present invention provides a pharmaceutical composition comprising the above-mentioned lappaconitine.

[0034] Furthermore, the pharmaceutical composition also includes a pharmacodynamically acceptable carrier or excipient.

[0035] Furthermore, the pharmaceutical composition also includes a synergist;

[0036] The synergist is one or more of the following substances:

[0037] Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram, venlafaxine, duloxetine, mirtazapine, bupropion, agomelatine, trazodone, reboxetine, imipramine, amitriptyline, clomipramine, doxepin, maprotiline, moclobemide, Shugan Jieyu capsule, St. John's wort extract, flupentixol-melitracen, etc.

[0038] That is, the pharmaceutical composition containing the lappa lactoporphyrin of the present invention as an active ingredient and conventional pharmaceutical excipients or adjuvants or carriers is also included in the present invention.

[0039] Furthermore, the dosage form of the pharmaceutical composition is tablets, capsules, granules, oral liquid, granules, pills or micropills.

[0040] In another aspect, the present invention provides the use of the above-mentioned lappaconitine or the above-mentioned pharmaceutical composition in antidepressant drugs.

[0041] Compared with the prior art, the present invention has the following advantages:

[0042] (1) The experimental results show that the lappaconitine provided by the present invention exhibits significant antidepressant activity in the mouse behavioral despair model tail suspension test, which is better than the positive drug fluoxetine and can be used to develop antidepressant drugs;

[0043] (2) The present invention provides a method for extracting lappa acetoin from aconite with simple operation, good reproducibility and high extraction purity. DETAILED DESCRIPTION

[0044] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments.

[0045] It should be understood that the specific embodiments described herein are only used to explain the present invention, and are not used to limit the present invention.

[0046] In the examples, unless otherwise specified, all the means used are conventional means in the art.

[0047] As used herein, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, step, method, article, or apparatus that comprises the listed elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, step, method, article, or apparatus.

[0048] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0049] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0050] In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0051] Example 1

[0052] A C 18 The preparation method of the diterpene alkaloid lappaconitine comprises the following steps:

[0053] S1, take dried aconite, add solvent to reflux extraction, combine the extracts and concentrate to obtain an extract; specifically, take 200.5kg of dried aconite, 95% ethanol aqueous solution with a mass of 10 times the amount of aconite as a solvent, reflux extraction three times, each extraction for 2h, combine the extracts and concentrate to obtain 6kg of extract;

[0054] S2, adding the extract to dilute hydrochloric acid to fully dissolve and suspend, filtering and removing impurities to obtain an acid aqueous solution; extracting the acid aqueous solution once with dichloromethane, filtering out the primary extract, and obtaining a filtered acid aqueous solution; adjusting the pH of the filtered acid aqueous solution to alkaline; and then performing a secondary extraction with dichloromethane to obtain a secondary extract;

[0055] In this embodiment, the extract is added to 10 times the mass of 0.5% dilute hydrochloric acid (60L) to fully dissolve and suspend, and then filtered to remove impurities to obtain an acid aqueous solution; the acid aqueous solution is extracted 3 times with 1.5 times the volume of dichloromethane to obtain 2.5kg of acidified dichloromethane primary extract (discarded) and 1.2kg of filtered acid aqueous solution, i.e., the acid water layer, and the filtered acid aqueous solution is adjusted to pH = 9 with sodium hydroxide, and then extracted with dichloromethane, and the dichloromethane secondary extract is 500g.

[0056] S3. The secondary extract was subjected to gradient elution using a dichloromethane-methanol solution to obtain a fraction B. When the fraction B was identified using a silica gel thin layer, the Rf value corresponding to the fraction B was 0.76-0.80.

[0057] The secondary extract was subjected to gradient elution by silica gel column chromatography using dichloromethane-methanol with a volume ratio of 100:0, 95:5, 92:8, 90:10, 85:15, 75:25, 65:35, 50:50, and 0:100, respectively, to obtain fractions 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, and 81-90, a total of 90 fractions were collected and identified by silica gel thin layer chromatography. According to the brick-red spots revealed by potassium iodide reagent, the Rf values ​​were observed to be 0.82-0.86 (fractions 1-10 ), 0.76-0.80 (fraction 11-20), 0.72-0.75 (fraction 21-30), 0.65-0.70 (fraction 31-40), 0.56-0.62 (fraction 41-50), 0.50-0.54 (fraction 51-60), 0.42-0.48 (fraction 61-70), 0.30-0.38 (fraction 71-80), 0.25-0.28 (fraction 81-90) and similar fractions were combined to obtain fractions A, B, C, D, E, F, G, H and I in turn; among them, fractions 11-20 were combined to obtain fraction B.

[0058] According to the brick-red spots revealed by potassium bismuth iodide reagent and the characteristic ultraviolet absorption (λ max =230nm) Fraction B was selected for the next separation.

[0059] S4. Fraction B is gradient eluted with a methanol-water mixed solution to obtain fraction B2; when detected by silica gel thin layer, the Rf value corresponding to fraction B2 is 0.45-0.49. When fraction B2 is eluted, the volume ratio of methanol to water in the methanol-water mixed solution is (25:75)-(35:65); preferably, the volume ratio of methanol to water is 30:70. And, the methanol-water mixed solution contains 0.01-1.1V% formic acid, preferably 0.05V% formic acid.

[0060] The specific operation includes: fraction B is subjected to ODS column chromatography, and gradient elution is performed using methanol-water (containing 0.05% formic acid) with a volume ratio of 20:80, 30:70, 40:60, 50:50, 60:40, 80:20, and 100:0, to obtain fractions 1-6, 7-15, 16-23, 24-36, 37-45, 46-57, and 58-68 in sequence, and a total of 68 fractions are collected, and the fractions are identified by silica gel thin layer chromatography. The observed Rf values ​​of the brick-red spots were 0.35-0.44 (fractions 1-6), 0.45-0.49 (fractions 7-15), 0.50-0.60 (fractions 16-23), 0.61-0.69 (fractions 24-36), 0.70-0.74 (fractions 37-45), 0.75-0.79 (fractions 46-57), and 0.80-0.89 (fractions 58-68). Similar fractions were combined into 7 fractions B1 to B7. Fractions 7-15 were combined to obtain fraction B2.

[0061] According to the brick-red spots revealed by potassium bismuth iodide reagent and the characteristic ultraviolet absorption (λ max =230nm) and select fraction B2 for the next separation.

[0062] S5. Fraction B2 is gradient eluted with a methanol-water solution to obtain fraction K3; when detected by silica gel thin layer, the K3 value corresponding to fraction B2 is 0.64-0.76. The volume ratio of methanol to water in the methanol-water solution when fraction K3 is eluted (i.e., corresponding to fraction K3) is (65:35)-(75:25); preferably, the volume ratio of methanol to water is 70:30.

[0063] The specific operation includes: subjecting fraction B2 to Sephadex LH-20 gel column chromatography, using a methanol-water gradient elution with a volume ratio of 0:100, 30:70, 70:30, and 100:0, and collecting fractions 1-4, 5-13, 14-19, and 20-24 in sequence. After a total of 24 fractions have been collected, silica gel thin layer chromatography is used for identification. According to the brick-red spots revealed by potassium bismuth iodide reagent, the Rf values ​​are observed to be 0.30-0.55 (fraction 1-4), 0.56-0.63 (fraction 5-13), 0.64-0.76 (fraction 14-19), and 0.77-0.85 (fraction 20-24), respectively. Similar fractions are combined into 4 fractions K1 to K4; fractions 14-19 are combined to obtain fraction K3.

[0064] In this step, the brick red spots shown by the bismuth potassium iodide reagent and the characteristic ultraviolet absorption (λ max =230nm) fraction K3 was selected for the next separation.

[0065] S6. Separate the lappaconitine from fraction K3 using RP-HPLC; the mobile phase used in the RP-HPLC method is an acetonitrile-water mixed solution. The volume ratio of acetonitrile to water in the acetonitrile-water mixed solution is (44:56)-(48:52); the acetonitrile-water mixed solution contains 0.01-0.5V% trifluoroacetic acid. Preferably, the volume ratio of acetonitrile to water in the acetonitrile-water mixed solution is 46:54, and the acetonitrile-water mixed solution contains 0.1V% trifluoroacetic acid.

[0066] The specific operation includes: using acetonitrile-water mixed solution (containing 0.1% trifluoroacetic acid) as the mobile phase, using HPLC method, with the volume ratio of acetonitrile to water being 46:54, using C 18 The chromatographic column was used to prepare lappaconitine (t R =18.5 min, purity 95%), defined as compound 1.

[0067] The physical properties and test data of the compound 1 prepared in Example 1 are as follows:

[0068] White amorphous powder, easily soluble in methanol. High resolution mass spectrometry (HR-ESI-MS) m / z 585.3160 ​​([M+H] + The calculated value is 585.3170), and combined with NMR data, its molecular formula is determined to be C 32 H 44 N2O8, its unsaturation is calculated to be 12, and its NMR data are as follows:

[0069] 1 H NMR(400MHz,CDCl3)δ:11.04(1H,s,NHCO3),8.64(1H,d,J=8.4Hz,H-6′,Ar-H),7.91(1H,dd,J=8.0,1.2Hz,H-3′,Ar-H),7.47(1H,td,J=8.0,1.6H z,H-4′,Ar-H),7.00(1H,td,J=8.0,1.2Hz,H-5′,Ar-H),3.30,3.31,3.38(each 3H,s,3×OCH3),2.20(3H,s,COCH3),1.11(3H,t,J=6.8Hz,N-CH2CH3);

[0070] 13C NMR (100MHz, CDCl3) δ: 169.0 (NHCOCH3), 167.5 (ArCO), 141.7 (C-2′), 134.5 (C-4′), 131.1 (C-6′), 122.4 (C-5′), 12 0.3(C-3′),115.8(C-1′),90.2(C-14),84.7(C-4),84.3(C-1),82.9(C-16),78.5(C-9),75.7(C-8),61.6(C-17),5 7.8(14-OCH3),56.6(1-OCH3),56.2(16-OCH3),55.6(C-19),50.8(C-11),49.8(C-10),49.1(C-21),48.5(C-5),47 .6(C-7),44.8(C-15),36.3(C-13),31.8(C-3),26.8(C-6),26.2(C-2),25.5(NHCOCH3),24.1(C-12),13.5(C-22).

[0071] The C 18 The structural formula of the diterpene alkaloid lappaconitine is shown below:

[0072]

[0073] Comparative Example 1

[0074] Comparative Example 1 of the present invention provides C 18 The preparation method of the diterpene alkaloid lappaconitine has the same steps as those in Example 1, except that in step S6, the aqueous mobile phase used in separating fraction K3 by RP-HPLC does not contain trifluoroacetic acid.

[0075] The compound prepared in Comparative Example 1 had severe peak tailing during the preparation process. Liquid phase analysis after preparation revealed that the compound contained a large amount of impurities. The purity of the prepared compound 1 was less than 50%.

[0076] Comparative Example 2

[0077] Comparative Example 2 of the present invention provides C 18 The preparation method of the diterpene alkaloid lappaconitine is similar to that of Example 1, except that in step S4, when fraction B is subjected to ODS column chromatography, methanol-water (without formic acid) with an initial volume ratio of 20:80 is used for elution. The compound of Comparative Example 2 could not be detected during the subsequent fraction preparation process, and the results showed that compound 1 could not be prepared.

[0078] Test Example 1

[0079] This test example discloses the antidepressant effect of the above-mentioned compound lappaconitine in the mouse behavioral despair model experiment (the gold standard for antidepressant drug screening).

[0080] 1. Experimental materials and instruments

[0081] Fluoxetine hydrochloride was purchased from Shanghai Yuanye Biotechnology Co., Ltd.; norcoclaurine and methylcoconutine were purchased from Shanghai Standard Standard Technical Services Co., Ltd.; total alkaloids from Aconitum carmichaelii; lappa lactopin.

[0082] ZIL-2 mouse autonomous activity box (Shanghai Xinman Science and Education Equipment Co., Ltd.);

[0083] YLS-18A mouse tail suspension instrument (Anhui Zhenghua Biological Instrument Equipment Co., Ltd.); electronic balance (Beijing Sartorius Scientific Instrument Co., Ltd.).

[0084] 2. Experimental Animals

[0085] ICR mice, male, weighing 18-22g, SPF grade, provided by Weitong Lihua, animal license number: SYXK (Beijing) 2023-0001. The animals were kept in an environment with a temperature of 23±2℃, a humidity of 50%±10%, and a lighting time of 12h per day (lighting from 7:00 to 19:00). The experiments were carried out after the animals were raised for 3 days. They were fasted for 6h before the start of the behavioral experiment and had free access to water.

[0086] 3. Experimental Methods

[0087] 70 ICR male mice were divided into 7 groups in descending order of the number of spontaneous activities according to the animal screening, namely, blank group (same volume of normal saline), positive drug fluoxetine hydrochloride group (10 mg / kg), methyltaurine group (10 mg / kg), higenamine group (10 mg / kg), total alkaloids of aconite group (10 mg / kg), low-dose lappaconitine group (0.03 mg / kg), and high-dose lappaconitine group (0.3 mg / kg); 10 mice in each group were numbered respectively. All drugs were added to normal saline to form a suspension, and each group was gavaged once a day, with a volume of 0.1 ml / 10 g body weight. After 3 consecutive days of administration, spontaneous activity experiments were performed on the 4th day, and tail suspension experiments were performed on the 5th day.

[0088] 3. Experimental results

[0089] As shown in Table 1, compared with the blank group, the low and high dose groups of higenamine (0.03 and 0.3 mg / kg) can significantly shorten the immobility time of mice in the tail suspension test, showing significant antidepressant activity, which is significantly better than the positive drugs fluoxetine (10 mg / kg, the first-line chemical drug for the clinical treatment of depression), methyltaurine (10 mg / kg), norhiazine (10 mg / kg) and total alkaloids of aconite (10 mg / kg).

[0090] Table 1 Effects of lappaconitine on tail suspension immobility time in behavioral despair model mice

[0091]

[0092] (mean ± standard deviation, compared with the blank group, *** P<0.001)

[0093] As shown in Table 2, compared with the blank group, each drug-treated group had no significant effect on the spontaneous activity of mice in the open field test, indicating that the effect of each drug-treated group on the immobility time of mice in the tail suspension test was not related to neural excitability.

[0094] Table 2 Effects of lappaconitine on horizontal movement distance in the open field of behavioral despair model mice

[0095]

[0096] In summary, the C 18 The diterpene alkaloid lappaconitine has antidepressant activity that is significantly superior to fluoxetine, the first-line drug for depression, and can be used as a drug precursor for the treatment of depression.

[0097] Application Example 1

[0098] The application example of the present invention discloses a capsule preparation using lappaconitine as a raw material drug, and its components are as follows:

[0099]

[0100] The specific preparation process is as follows:

[0101] Take lappaconitine, starch and sodium metabisulfite and mix them evenly, add anhydrous ethanol to make a soft material, pass through a 24-mesh sieve, make granules, dry, add magnesium stearate, mix well, and put into capsules.

[0102] Application Example 2

[0103] The application example of the present invention discloses a granule preparation using the compound lappaconitine as a raw material drug, and the components thereof are as follows:

[0104] Lappaconitine 4.0mg

[0105] Starch 6.0g

[0106] Sodium bisulfite 0.2g

[0107] Magnesium stearate 0.2g

[0108] Anhydrous ethanol

[0109] Makes 100 bags.

[0110] The specific preparation process is as follows:

[0111] Take lappaconitine, mix it with starch and sodium bisulfite, add anhydrous ethanol to make a soft material, pass it through a 24-mesh sieve, make it into granules, dry it, add magnesium stearate, mix it evenly, and pack it in bags.

[0112] Application Example 3

[0113] The application example of the present invention discloses an oral liquid using the compound lappaconitine as a raw material drug, and its components are as follows:

[0114]

[0115] The specific preparation process is as follows:

[0116] After the above components are mixed evenly, they can be packaged using a conventional oral liquid preparation method.

[0117] Application Example 4

[0118] The application example of the present invention discloses an injection with the compound lappaconitine as the raw material, and its components are as follows:

[0119]

[0120] The specific preparation process is as follows:

[0121] After the above components are mixed evenly, 100 vials can be obtained using conventional preparation methods for injections.

[0122] Application Example 5

[0123] The application example of the present invention discloses a tablet with compounds lappaconitine and fluoxetine as raw materials, and its components are as follows:

[0124]

[0125] The specific preparation process is as follows:

[0126] Take lappaconitine, fluoxetine, hydroxypropyl methylcellulose, talc, lactose and magnesium stearate, mix them evenly, add anhydrous ethanol to make a soft material, pass through a 24-mesh sieve, make granules, dry, add magnesium stearate, mix evenly, and press into tablets.

[0127] Application Example 6

[0128] The application example of the present invention discloses a capsule preparation using the compounds lappaconitine and rulothione as raw materials, and the components thereof are as follows:

[0129]

[0130] The specific preparation process is as follows:

[0131] Take lappa acetylcholine, Luyoutai and sodium metabisulfite and mix them evenly, then add anhydrous ethanol to make a soft material, pass through a 24-mesh sieve to make granules, dry, add magnesium stearate, mix evenly and put into capsules.

[0132] Application Example 7

[0133] The application example of the present invention discloses an injection with lappaconitine and paroxetine as raw materials, and its components are as follows:

[0134]

[0135] The specific preparation process is as follows:

[0136] After the above components are mixed evenly, 100 vials can be obtained using a conventional injection preparation method.

[0137] The above-mentioned embodiments only express several implementation modes of the present invention, and the description thereof is relatively specific and detailed, but it should not be understood as limiting the scope of the invention patent.

[0138] It should be noted that, for those skilled in the art, several modifications and improvements can be made without departing from the concept of the present invention, and these modifications and improvements all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A lappaconitine, It is characterized in that It has the structure shown in formula (1):

2. A method for preparing lappaconitine according to claim 1, It is characterized in that The lappaconitine is extracted and separated from aconite root.

3. The preparation method according to claim 2, It is characterized in that The following steps are involved: S1. Take dried aconite root, add solvent to reflux and extract, combine the extracts and concentrate to obtain an extract; S2, adding the extract to dilute hydrochloric acid to fully dissolve and suspend, filtering and removing impurities to obtain an acid aqueous solution; Extracting the acid aqueous solution once with dichloromethane, filtering out the primary extract to obtain a filtered acid aqueous solution; adjusting the pH of the filtered acid aqueous solution to be alkaline; and then extracting it twice with dichloromethane to obtain a secondary extract; S3, gradient eluting the secondary extract with a dichloromethane-methanol solution to obtain a fraction B; when detected by silica gel thin layer, the Rf value of the fraction B is 0.76-0.80; S4, using a methanol-water mixed solution to gradiently elute fraction B to obtain fraction B2; when using silica gel thin layer detection, the Rf value corresponding to fraction B2 is 0.45-0.49; S5, gradient eluting fraction B2 with methanol-water solution to obtain fraction K3; When using silica gel thin layer analysis, the K3 value corresponding to fraction B2 was 0.64-0.76; S6. Separating and obtaining the lappaconitine from fraction K3 by RP-HPLC; The mobile phase used in the RP-HPLC method was a mixed solution of acetonitrile and water.

4. The preparation method according to claim 3, It is characterized in that In step S2, the filtered acid aqueous solution is adjusted to a pH of 8-11 with sodium hydroxide.

5. The preparation method according to claim 3, It is characterized in that In step S2, the filtered acid aqueous solution is adjusted to a pH of 9 with sodium hydroxide.

6. The preparation method according to claim 3, It is characterized in that In step S2, the extract is added into 8-15 times the mass of dilute hydrochloric acid to fully dissolve and suspend, and then filtered to remove impurities to obtain an acid aqueous solution.

7. The preparation method according to claim 3, It is characterized in that The concentration of the dilute hydrochloric acid is 0.1-1.0%.

8. The preparation method according to claim 3, It is characterized in that In step S3, the secondary extract is separated by silica gel column chromatography to obtain fraction B; based on the total volume of 100, the volume ratio of dichloromethane to methanol in the dichloromethane-methanol solution when fraction B is eluted is (97:3)-(93:7).

9. A pharmaceutical composition, It is characterized in that It includes the lappaconitine described in claim 1.

10. Use of the lappaconitine according to claim 1 and / or the pharmaceutical composition according to claim 9 in antidepressant drugs.

Citation Information

Patent Citations

  • Method for extracting lappaconitine from aconitum sinomontanum plant roots

    CN104098510A

  • High-purity lappaconitine and preparation method thereof

    CN108409657A

  • Preparation method of lappaconitine

    CN117700360A

  • Method for detecting effective components of radix aconiti carmichaeli

    CN118010898A